Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2025-12-25 @ 4:25 AM
NCT ID:
NCT03149120
Eligibility Criteria:
Inclusion Criteria:
* Histologic diagnosis of metastatic or unresectable soft tissue or bone sarcoma
* No prior therapy with nivolumab in either cohorts or with pazopanib in the combination cohort
* At least one line of systemic therapy or ineligibility for an anthracycline based chemotherapy
* At least 2 distinct measurable metastatic sites
* Adequate organ and marrow function as defined by initial laboratory tests
* Life expectancy \> 3 months
* Stable brain metastases for at least 4 weeks and no steroid dependence
Exclusion Criteria:
* Autoimmune disease Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drugs hazardous or obscure the interpretation of adverse events
* Concomitant therapy with any non-study immunotherapy regimens, cytotoxic chemotherapy, immunosuppressive agents, other investigation therapies Chronic use of systemic corticosteroids greater than prednisone 10 mg daily or its equivalent
* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 5 months after cessation of study drug, or have a positive pregnancy test at baseline, or are pregnant or breastfeeding;
* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical illness.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
100 Years
Study:
NCT03149120
Study Brief:
Protocol Section:
NCT03149120